Matthaios Papadimitriou-Olivgeris1,2, Anastasia Spiliopoulou3, Fotini Fligou4, Iris Spiliopoulou3, Lora Tanaseskou4, Georgios Karpetas4, Markos Marangos1, Evangelos D Anastassiou3, Myrto Christofidou5. 1. Division of Infectious Diseases, School of Medicine, University of Patras, Patras, Greece. 2. Department of Internal Medicine, Hôpital du Jura, Fbg des Capucins 30, 2800, Delémont, Switzerland. 3. Department of Microbiology, School of Medicine, University of Patras, University Campus, 26504, Patras, Greece. 4. Division of Anaesthesiology and Intensive Care Medicine, School of Medicine, University of Patras, Patras, Greece. 5. Department of Microbiology, School of Medicine, University of Patras, University Campus, 26504, Patras, Greece. christof@med.upatras.gr.
Abstract
PURPOSE: The aim of the present study is to identify risk factors for development and predictors of mortality of candidaemia among critically ill patients. METHODS: A 1:7 case-control study was conducted during a 4-year period (2012-2015) in a Greek Intensive Care Unit (ICU). Candidaemia was confirmed by positive blood cultures. All yeasts were identified using API 20C AUX System or Vitek 2 Advanced Expert System. Epidemiologic data were collected from the ICU computerized database and patients' chart reviews. RESULTS: Fifty-three patients developed candidaemia with non-albicans species being the predominant ones (33 patients, 62.3%). Multivariate analysis found that prior emergency surgery, malignancy, hospitalization during summer months, prior septic shock by KPC-producing Klebsiella pneumoniae and number of antibiotics administered were independently associated with candidaemia, while, prior administration of azole was a protective factor. Non-albicans candidaemia was associated with number of antibiotics administered and prior administration of echinocandin. Mortality of 14 days was 28.3% (15 patients) and was associated with SOFA score upon infection onset and septic shock, while, appropriate empirical antifungal treatment was associated with better survival. CONCLUSIONS: Prophylactic azole administration prevents development of candidaemia, while, echinocandin administration predisposes to non-albicans candidaemia. Empirical administration of an appropriate antifungal agent is associated with better survival.
PURPOSE: The aim of the present study is to identify risk factors for development and predictors of mortality of candidaemia among critically ill patients. METHODS: A 1:7 case-control study was conducted during a 4-year period (2012-2015) in a Greek Intensive Care Unit (ICU). Candidaemia was confirmed by positive blood cultures. All yeasts were identified using API 20C AUX System or Vitek 2 Advanced Expert System. Epidemiologic data were collected from the ICU computerized database and patients' chart reviews. RESULTS: Fifty-three patients developed candidaemia with non-albicans species being the predominant ones (33 patients, 62.3%). Multivariate analysis found that prior emergency surgery, malignancy, hospitalization during summer months, prior septic shock by KPC-producing Klebsiella pneumoniae and number of antibiotics administered were independently associated with candidaemia, while, prior administration of azole was a protective factor. Non-albicans candidaemia was associated with number of antibiotics administered and prior administration of echinocandin. Mortality of 14 days was 28.3% (15 patients) and was associated with SOFA score upon infection onset and septic shock, while, appropriate empirical antifungal treatment was associated with better survival. CONCLUSIONS: Prophylactic azole administration prevents development of candidaemia, while, echinocandin administration predisposes to non-albicans candidaemia. Empirical administration of an appropriate antifungal agent is associated with better survival.
Authors: O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann Journal: Clin Microbiol Infect Date: 2012-12 Impact factor: 8.067
Authors: Luis Ostrosky-Zeichner; Shmuel Shoham; Jose Vazquez; Annette Reboli; Robert Betts; Michelle A Barron; Mindy Schuster; Marc A Judson; Sanjay G Revankar; Juan Pablo Caeiro; Julie E Mangino; David Mushatt; Roger Bedimo; Alison Freifeld; Minh Hong Nguyen; Carol A Kauffman; William E Dismukes; Andrew O Westfall; Jeanna Beth Deerman; Craig Wood; Jack D Sobel; Peter G Pappas Journal: Clin Infect Dis Date: 2014-02-18 Impact factor: 9.079
Authors: Christian Ortega-Loubon; Beatriz Cano-Hernández; Rodrigo Poves-Alvarez; María Fe Muñoz-Moreno; Patricia Román-García; Sara Balbás-Alvarez; Olga de la Varga-Martínez; Esther Gómez-Sánchez; Estefanía Gómez-Pesquera; Mario Lorenzo-López; Eduardo Tamayo; María Heredia-Rodríguez Journal: J Clin Med Date: 2019-09-20 Impact factor: 4.241